Hickory-Pecan Mix Allergy Shots (SCIT)
Hickory-pecan is the workhorse Juglandaceae SCIT preparation — a combined Carya extract blending pecan (C. illinoinensis) and shagbark hickory (C. ovata) to exploit near-complete intra-genus cross-reactivity, covering the full Carya genus in a single extract for South-Central and Mid-Atlantic patients.
Hickory-Pecan Mix Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to hickory-pecan mix — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of hickory-pecan mix allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of hickory-pecan mix immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of hickory-pecan mix extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for hickory-pecan mix allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing hickory-pecan mix extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription hickory-pecan mix immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat hickory-pecan mix allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is Hickory-Pecan Mix?
The biology, taxonomy, and clinical fingerprint of Hickory-Pecan Mix — the foundation of how SCIT targets it.
Hickory-pecan mix combines catkin pollen from the two most clinically prominent Carya species — pecan (C. illinoinensis, dominant in the South-Central US) and shagbark hickory (C. ovata, most allergenic Carya in the Mid-Atlantic) — into a single SCIT preparation that exploits essentially complete intra-genus cross-reactivity.
- Scientific name
- Carya spp. (C. illinoinensis + C. ovata + regional species)
- Family
- JuglandaceaeWalnut family
- Type
- Deciduous tree pollen blend
- Native to
- Combined coverage: C. illinoinensis (South-Central US pecan belt) + C. ovata (Mid-Atlantic and eastern US)
- Allergen proteins
- NO IUIS-named pollen allergen for any Carya species as of May 2026 — the most significant evidence gap in US Juglandaceae allergenologyCuevas-Zuviría et al. (J Proteomics 2021) identified 17 IgE-binding proteins in pecan pollen — likely shared across Carya genus but not individually characterizedNamed Carya allergens at WHO/IUIS are ALL kernel (food) proteins from pecan (C. illinoinensis): Car i 1 (2S albumin), Car i 2 (vicilin), Car i 4 (11S legumin)CRITICAL: Hickory-pecan pollen SCIT does NOT treat Car i 1/2/4 kernel food allergy or pecan/hickory/walnut kernel anaphylaxis
- Particle size
- 43–53 μm (pecan); ~30–45 μm (shagbark hickory)
- Avoidance difficulty
- Nearly impossible
How Hickory-Pecan Mix Allergy Presents
Symptoms by body system — useful for distinguishing Hickory-Pecan Mix sensitivity from overlapping allergies and infections.
Respiratory (Pollen — Inhalant Allergy)
- Sneezing and profuse rhinorrhea during mid-April through May Carya pollen season across the South-Central and Mid-Atlantic US
- Nasal congestion on high-pollen days in TX, OK, LA, AR, MS, and the Mid-Atlantic (VA, MD, PA, DC)
- Itchy, swollen nasal passages during the 4–6 week Carya catkin release season — often overlapping with oak season
- Allergic asthma exacerbations in sensitized patients during peak Carya weeks
- Post-nasal drip and chronic cough from sustained hickory-pecan pollen exposure
Ocular
- Bilateral eye itching and watering during the April–May Carya season
- Conjunctival redness on high-pollen days — particularly in areas with both pecan orchards and native hickory canopy
- Morning eyelid puffiness from overnight pollen settling
- Photophobia and reduced visual comfort during peak Carya weeks
Dermal
- CRITICAL DISAMBIGUATION: Pecan and hickory kernel food allergy is driven by heat-stable storage proteins (Car i 1/2/4 from pecan; cross-reactive with hickory and walnut kernels) — these are NOT treated by hickory-pecan pollen SCIT. If you experience systemic reactions after eating pecans, hickory nuts, or walnuts, carry an epinephrine auto-injector regardless of SCIT status.
- Contact dermatitis from hickory or pecan tree sap or green hull handling
- Atopic dermatitis flares coinciding with Carya pollen season in susceptible patients
Systemic
- Fatigue and sleep disruption from spring Carya allergy in the South-Central and Mid-Atlantic US, amplified by concurrent oak and ash exposure
- Impaired outdoor activity during prime spring season — Carya season coincides with peak outdoor work in agricultural South-Central regions
- Anxiety around pecan and hickory kernel consumption if co-existing storage-protein food allergy is present
- Diagnostic confusion between the pollen allergy (treatable by SCIT) and the kernel food allergy (not treatable by SCIT) remains common and requires component testing
Hickory-pecan is the workhorse Juglandaceae mix in the South-Central and Mid-Atlantic — one extract to cover the entire Carya genus, because intra-genus cross-reactivity is essentially complete. The clinical magnitude is there (Hoffman's 27.8% in US children with rhinitis), but we have no Phase 3 trial and no named IUIS pollen allergen — this is the textbook example of family-level evidence carrying clinical practice.
When & Where Hickory-Pecan Mix Peaks
Allergen intensity by month and by state. Useful for timing SCIT start dates and travel planning.
12-Month Intensity
Peak: mid-April through May — Carya genus pollen release across the South-Central and Mid-Atlantic US· ~4–6 weeks; hickory pollen (Mid-Atlantic) often starts a week before pecan (South-Central) in many years; substantial overlap with oak season
US Exposure Map
9 high-intensity statesWhat Hickory-Pecan Mix Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
Hickory-pecan cross-reactivity is built on the essentially complete intra-Carya pollen protein overlap — the scientific and clinical rationale for combining these species into one extract. Cross-genus Juglandaceae cross-reactivity with walnut (Juglans) is documented at the kernel level (storage-protein cross-reactivity) and inferred at the pollen level.
Within-Carya; essentially complete pollen cross-reactivity — this is why the mix works
Within-Carya; essentially complete; shagbark ranked most allergenic Carya species
Kernel storage-protein cross-reactivity (Car i 1/2/4, Jug r 1/2/4) — NOT addressed by pollen SCIT
Is SCIT Right for Your Hickory-Pecan Mix Allergy?
Answer five questions to assess whether hickory-pecan SCIT is appropriate for your South-Central or Mid-Atlantic spring allergy profile.
How severe are your spring symptoms during April–May Carya pollen season?
The Hickory-Pecan Mix SCIT Protocol
Hickory-pecan SCIT uses a non-standardized Carya combined extract — typically blending C. illinoinensis (pecan) and C. ovata (shagbark hickory), with some manufacturers adding C. tomentosa (mockernut) and C. cordiformis (bitternut). In southern Mix B/Mix C regional protocols, the hickory-pecan maintenance dose may be pushed to 1:50 w/v where Carya is the dominant spring allergen. Fall or winter build-up initiation is preferred to avoid active Carya season co-exposure.
Injections begin at 1:10,000 w/v and increase incrementally. South-Central patients should start in fall (September–November) to be at or near maintenance before mid-April pecan season. Mid-Atlantic patients targeting the shagbark season should similarly start in fall to avoid the April peak. Patients with confirmed kernel food allergy (Car i 1/2/4) must continue strict kernel avoidance and carry an epinephrine auto-injector throughout SCIT. Traditionally each injection was followed by a 30-minute observation period; with Curex, eligible patients self-administer the same escalation schedule at home, and the first dose plus every dose increase are supervised live over Zoom with a prescribed epinephrine auto-injector confirmed on hand.
Monthly maintenance at the target dose sustains full Carya genus-level tolerance. In regional southern Mix B/Mix C protocols where hickory-pecan is the dominant clinical allergen, some allergists push maintenance to 1:50 w/v for greater clinical effect — this is standard regional practice, not based on formal RCT data. Cross-protection to walnut (Juglans) at the pollen level is assumed but not formally characterized.
Lasting benefit of 7–12+ years expected with full course completion. SCIT discontinuation has no impact on kernel food allergy management — strict avoidance and epinephrine carry continue indefinitely for patients with Car i 1/2/4 sensitization.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for Hickory-Pecan Mix SCIT
Hickory-pecan SCIT has no species-specific or combined-extract RCT. Efficacy is honestly characterized as extrapolated from the general Carya sensitization evidence base (Hoffman 1996, Bucholtz series) and the AAAAI Practice Parameter for allergen immunotherapy.
- Carya SPT positivity in US children with rhinitis28%Hoffman 1996 (cited Thermo Fisher t22): 27.8% SPT-positive in 209 US rhinitis patients
- Pecan/hickory reactivity in NYC tree-allergic patients27%Bucholtz et al. NYC series: 27.1% of 371 tree-allergic patients
- General inhalant SCIT efficacy for non-standardized tree pollen extracts55%Cox L et al., J Allergy Clin Immunol 2011 — AAAAI Practice Parameter general evidence framework
Hickory-pecan SCIT has no Phase 3 RCT and no formally named pollen allergens. The Hoffman 1996 and Bucholtz sensitization data establish that Carya genus pollen is a major aeroallergen affecting 27–28% of US rhinitis patients — a clinical magnitude justifying immunotherapy despite the evidence gaps. The combined hickory-pecan formulation exploits essentially complete intra-Carya cross-reactivity to provide full genus coverage in one extract, following the same efficiency rationale as birch-mix for Betula or oak-mix for Quercus.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Hickory-Pecan Mix SCIT Side Effects
Hickory-pecan SCIT side effects follow the standard inhalant SCIT profile. Fall/winter build-up initiation is strongly preferred for both South-Central (avoiding April pecan peak) and Mid-Atlantic (avoiding April shagbark peak) patients.
Local reactions
4 documentedSystemic reactions
4 documentedCRITICAL: Patients with confirmed pecan or hickory kernel food allergy (Car i 1/2/4-driven storage-protein allergy, or cross-reactive walnut Jug r 1/2/4) must continue strict kernel avoidance and carry an epinephrine auto-injector throughout and after hickory-pecan pollen SCIT. Pollen SCIT does not desensitize kernel storage-protein food allergy. This must be communicated clearly and repeatedly throughout the SCIT course.
SCIT vs Alternatives for Hickory-Pecan Mix
Patients with Carya genus sensitization — addressing hickory and pecan pollen inhalant allergy — have four main options. Kernel food allergy management is entirely separate and not addressed by any of these options.
| Criterion | SCITBest | SLIT | Avoidance | Medications |
|---|---|---|---|---|
| Effectiveness | Uncertain but standard practice — no Carya-specific RCT; Hoffman 1996 + Bucholtz data support clinical use | Uncertain — no hickory-pecan SLIT RCT; off-label Carya drops available | Low — Carya is widespread in South-Central and Mid-Atlantic landscape and agriculture | Moderate — antihistamines + nasal corticosteroids for mild-to-moderate symptoms |
| 5-yr cost | $3,500–$15,000 over 5 years | Varies by provider; sold as a general sublingual modality, not Curex's product | Low — HEPA, pollen masks, closed windows in April–May | $500–$2,000 over 5 years |
| Duration | 3–5 year course | 3–5 year course | Indefinite — no tolerance change | Indefinite — seasonal use |
| Convenience | At-home weekly self-injection with Curex; fall/winter start preferred; first dose and dose changes supervised live over Zoom | Daily at-home — no clinic required | High inconvenience in prime spring outdoor season | High convenience |
| Safety | Excellent — serum is USP <797> sterile-compounded, first dose and dose changes supervised live over Zoom, prescribed epinephrine auto-injector on hand, 30-min self-observation (pollen SCIT; kernel food allergy risks unchanged) | Favorable for pollen; does not affect kernel food allergy risk | Safe | Generally safe |
| Lasting effect | 7–12+ years after completion | Emerging data | None — symptoms return each April | None — must take every season |
SCITBest
SLIT
Avoidance
Medications
The hickory-pecan SCIT mix is the standard immunotherapy approach for the entire Carya genus — providing genus-level coverage from one extract for the 27% of US rhinitis patients who are Carya-sensitized across the South-Central and Mid-Atlantic regions. Curex now delivers that same SCIT as a weekly at-home injection at $129/month — the serum is sterile-compounded to USP <797>, your first dose and every dose change are supervised live over Zoom, and a prescribed epinephrine auto-injector is confirmed on hand — so you get full genus-level Carya coverage without the weekly clinic trip.
What Hickory-Pecan Mix SCIT Actually Costs
Hickory-pecan SCIT is covered by most major US insurers under standard allergy immunotherapy benefits when ordered by a board-certified allergist with documented sensitization. The combined preparation is typically billed as part of a multi-species regional tree mix (southern Mix B/Mix C). Pre-authorization should specify all Carya and Juglandaceae components in the extract and their clinical justification. Curex at-home IgE testing identifies specific hickory-pecan mix sensitization before allergist consultations, eliminating the need for an initial skin-test visit.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
Flat monthly subscription — includes consult, prescription, and at-home dosing for sublingual immunotherapy.
See if you qualifyStop guessing about your hickory-pecan mix allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
Hickory-Pecan Mix SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
Intra-Carya pollen cross-reactivity is essentially complete — meaning patients sensitized to pecan pollen (C. illinoinensis) typically react equally to shagbark hickory (C. ovata), mockernut (C. tomentosa), and bitternut (C. cordiformis) pollen via shared genus-level pollen proteins. Because the same antigenic epitopes are present across all Carya species, a single combined Carya extract provides equivalent genus-wide immunotherapy without the additional extract volume, complexity, and cost of separate species-specific vials. This follows the same efficiency rationale as birch-mix (covering multiple Betula species) or oak-mix (covering Q. alba and Q. rubra) — combining species within a genus where cross-reactivity is functionally complete.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.